FDA: BMD Can Be Surrogate Endpoint in Osteoporosis Trials
The FDA Biomarker Qualification Program approved changes in hip bone mineral density (BMD) after treatment to serve as a surrogate endpoint in place of bone fractures in anti-osteoporosis drug clinical trials involving postmenopausal women. The …